Navigation Links
Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Date:8/19/2007

THE WOODLANDS, Texas, Aug. 13 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the company will be making an oral presentation at the American Chemical Society National Meeting and Exposition in Boston, Massachusetts on Tuesday, August 21, 2007 at 2:50 p.m. Eastern Time. The presentation, based on the paper titled, "Modulation of peripheral serotonin levels by enzyme inhibitors for the potential treatment of irritable bowel syndrome (IBS)," will reveal the target of Lexicon's clinical candidate, LX1031, a potential treatment for irritable bowel syndrome (IBS), which is currently being investigated in a Phase 1b clinical trial in healthy volunteers. The presentation is part of the Division of Medicinal Chemistry general oral session and the paper number is 235.

Lexicon will also present a separate poster titled, "Open access mass-directed purification: Adaptation to diverse loading scales and compound polarities," at the same conference on August 19, 2007. The paper number is 174 and will be included in the Division of Medicinal Chemistry poster session which begins at 7:00 p.m. Eastern Time.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
3. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... MARLTON, N.J. , Feb. 27, 2015  Acsis ... collaboration and serialization solutions, announced today that John ... as a Supply & Demand Chain Executive ... chain executives who are leading initiatives to help prepare ... challenges of today,s business climate. This year,s list of ...
(Date:2/27/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... pro forma net operating loss (NOL) guidance and its ... position.  Isis, significantly improved financial results were due in ... payments the Company received from its partners.  Isis, pro ... nearly 60% improvement over its 2013 NOL of $40.2 ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... May 10, 2011 Omeros Corporation (NASDAQ: ... and commercializing products focused on inflammation, coagulopathies and disorders ... results for the first quarter of 2011. ... ended March 31, 2011 were $7.7 million compared to ...
... 2011 Pierrel Research USA, Inc. ( www.pierrel-research-usa.com ... global pharmaceutical services company ( www.pierrel.it ), announces ... with epinephrine 1:100,000 and Articaine hydrochloride 4% with ... of Articaine with epinephrine, an injectable dental anesthetic ...
Cached Medicine Technology:Omeros Corporation Reports First Quarter 2011 Financial Results 2Omeros Corporation Reports First Quarter 2011 Financial Results 3Omeros Corporation Reports First Quarter 2011 Financial Results 4Pierrel Research USA Launches Orabloc™ a New Purer Articaine 2Pierrel Research USA Launches Orabloc™ a New Purer Articaine 3
(Date:3/2/2015)... Final Cut Pro X plugin ... from Pixel Film Studios. , “The TranStatic Volume 2 plugin ... Christina Austin, CEO of Pixel Film Studios. “TranStatic Volume 2 ... Pro X editors toolbox.” , With TranStatic Volume 2 users ... altering static scrambling effects from Pixel Film Studios. Users have ...
(Date:3/1/2015)... (PRWEB) March 02, 2015 ... services and manage their practices compliantly and ... integrated all-inclusive solution. The interoperability between ... and a medical practice management system is ... long-term financial sustainability. A referral management and ...
(Date:3/1/2015)... (PRWEB) March 02, 2015 As ... web works co-founders, Michael Burns and Carita Weaver, ... addition to working with the Southlake Chamber of ... i5 web works recently launched a website for ... , A primary communications tool for Hill’s campaign, ...
(Date:3/1/2015)... Birmingham, Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... BOTOX® , which is approved to treat Overactive Bladder (OAB) ... urgency and frequency in adults when another type of medication ... This is a different treatment option that takes another ... itself. , BOTOX® works on the nerves and ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Adults who ... insurance rates for term or universal policies can now ... of the best life insurance companies for single adults ... system at http://quotespros.com/life-insurance.html . , The rate plans ... portal are tied to a number of life protection ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2
... Experience with Complex Rehab Market , , ... rehab specialist with 35 years of experience, has joined ... fastest growing complex rehab companies. O,Neill is an Assistive ... www.alliance-seating.com ) and is responsible for sales and service of ...
... muscular atrophy, a neurodegenerative disorder that causes the weakening ... and occurs in 1 in 6,000 live births. ... impressive results as a treatment for spinal muscular atrophy ... to translate the therapy to the human body. A ...
... Mo. Evolving HIV viral strains and the adverse ... treatments propel scientists to continue exploring alternative HIV ... Missouri researcher has identified broad-spectrum aptamers. Aptamers are ... reproducing. In lab tests, aptamers known as RT5, ...
... TriCipher will host an,informative Webinar detailing ... pharmaceutical and health care industries and strategies,for securing ... one hour webinar on December 16th brings together ... discuss how digital signatures have,benefited and streamlined research ...
... of voriconazole in combating fungal infections has been confirmed ... International Journal of Antimicrobial Agents ( www.elsevier.com/locate/ijaa ... with weakened immune systems, which can be caused by ... reinforces earlier findings that this drug is a potent ...
... Dec. 16 WellPoint, Inc. (NYSE: WLP ... today,announced plans to collaboratively partner with four Blue Cross ... to online, consumer-friendly,health care cost information. , ... WellPoint in this initiative are,Highmark Inc. (Pennsylvania), Premera Blue ...
Cached Medicine News:Health News:Veteran Rehab Specialist, Ted O'Neill, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:Researcher refining synthetic molecules to prevent HIV resistance 2Health News:Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures 2Health News:Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures 3Health News:Voriconazole: A highly potent treatment for fungal infections 2Health News:WellPoint Announces Collaborative Partnership to Expand Access to Health Care Provider Information 2Health News:WellPoint Announces Collaborative Partnership to Expand Access to Health Care Provider Information 3Health News:WellPoint Announces Collaborative Partnership to Expand Access to Health Care Provider Information 4
For the detection of pan specific pLDH, utilizing whole blood samples. Parabank excludes infected blood from the blood supply in the blood bags....
192 Test Enzyme Immunoassay for the detection of Human IgG antibodies to all four forms of Malaria....
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Malaria device / strip (2 line, PAN specific-pLDH)...
Medicine Products: